Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo

  • Authors:
    • Junfen Ma
    • Nan Li
    • Jimin Zhao
    • Jing Lu
    • Yanqiu Ma
    • Qinghua Zhu
    • Ziming Dong
    • Kangdong Liu
    • Liang Ming
  • View Affiliations

  • Published online on: April 21, 2017     https://doi.org/10.3892/ol.2017.6069
  • Pages: 4868-4874
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Replication-selective oncolytic virotherapy provides a novel modality to treat cancer by inducing cell death in tumor cells but not in normal cells. However, the utilization of oncolytic viruses as a stand‑alone treatment is problematic due to their poor transduction efficiency in vivo. H101 was the first oncolytic adenovirus (Ads) to be approved by the Chinese FDA, and exhibits modest antitumor effects when applied as a single agent. The multiple histone deacetylase inhibitor trichostatin A (TSA) has been demonstrated to potently enhance the spread and replication of oncolytic Ads in several infection-resistant types of cancer. The present study aimed to investigate the antitumor effects of H101 in combination with TSA on esophageal squamous cell carcinoma (ESCC) in vitro and in vivo, and determine the mechanisms underlying these effects. H101 and TSA in combination increased the survival of mice harboring human ESCC cell line‑tumor xenografts, as compared with mice treated with these agents individually. Therefore, TSA may enhance the antitumor effects of H101 in ESCC.
View Figures
View References

Related Articles

Journal Cover

June-2017
Volume 13 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ma J, Li N, Zhao J, Lu J, Ma Y, Zhu Q, Dong Z, Liu K and Ming L: Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo. Oncol Lett 13: 4868-4874, 2017.
APA
Ma, J., Li, N., Zhao, J., Lu, J., Ma, Y., Zhu, Q. ... Ming, L. (2017). Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo. Oncology Letters, 13, 4868-4874. https://doi.org/10.3892/ol.2017.6069
MLA
Ma, J., Li, N., Zhao, J., Lu, J., Ma, Y., Zhu, Q., Dong, Z., Liu, K., Ming, L."Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo". Oncology Letters 13.6 (2017): 4868-4874.
Chicago
Ma, J., Li, N., Zhao, J., Lu, J., Ma, Y., Zhu, Q., Dong, Z., Liu, K., Ming, L."Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo". Oncology Letters 13, no. 6 (2017): 4868-4874. https://doi.org/10.3892/ol.2017.6069